Fiche centre
Cancer Institute Hospital of JFCR
Kōtoku — Japan
Essais liés3clinical trials
VilleKōtokulocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05660967
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Epcoritamab | SEP | Phase 2 | NCT05660967 | EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | TERMINATED |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| Precemtabart tocentecan | Cancer | Phase 3 | NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | RECRUITING |